RxDoctor Payments Data

Jean Siedel, DO

Gynecologic Oncology · Ann Arbor, MINPI 1134448657

Payments from drug & device makers

What this record shows

Astrazeneca UK Limited accounts for 87.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gynecologic oncology clinicians in MI, where the typical reported total is $894.

$998in general payments, 2019–2025

Across 8 payments — averaging $124.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$868
  • AbbVie$130
$137,909in research payments, 2019–2025

Across 13 payments — averaging $10,608 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$65K
  • Daiichi Sankyo Inc.$56K
  • Merck$17K

What the payments were for

  • Travel & lodging$53754%
  • Food & beverage$46046%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited7$868
AbbVie1$130

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$998 in reported general payments places this provider in the 50th percentile of 43 gynecologic oncology providers in Michigan.

See all gynecologic oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$45,482
Medicare patients
100
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →